Psychedelic-focused biotech company Clearmind Medicine Inc. CMND CMNDF has signed a collaboration agreement with SciSparc Ltd. SPRC.The two companies will explore the potential for the creation of innovative compounds in the psychedelic area.
The collaboration will address, inter alia, examining the benefit of integrating the core technologies of each company by combining molecules from their respective development pipelines. The companies have begun the collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the collaboration between the parties.
"Our aim is to develop innovative, effective and safe psychedelic-derived therapeutics that could transform the mental health pharmaceutical market," said Clearmind CEO Adi Zuloff-Shani. "Clearmind has established a number of R&D partnerships, in order to continue strengthening its IP portfolio, including with leading academic, research and medical institutions. We're excited about the Collaboration with SciSparc, which we consider symbiotic, and expecting to reveal more details about the science behind the Collaboration soon."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.